A Brief History of Major Events in Oncology

Key Takeaways

• The National Cancer Act of 1971 remains the foundational U.S. policy milestone for modern federally organized cancer research.
• HER2-targeted trastuzumab and BCR-ABL–targeted imatinib established biomarker-driven commercial oncology.
• Immune checkpoint blockade opened a durable-response era that still dominates late-stage pipelines and deal premiums.
• For BD teams, timeline literacy matters: today’s ADC and multispecific wave sits on top of those earlier platform shifts.

What did the National Cancer Act change?

The National Cancer Institute’s historical milestones pages mark the National Cancer Act of 1971 as a defining expansion of federal cancer research capacity. That legislation strengthened NCI’s role and funding pathways that underwrote decades of cooperative group trials, SEER epidemiology, and intramural science.

Without that institutional scaffold, many later drug approvals would have lacked the trial networks and biomarker datasets sponsors now take for granted. Policy, not only molecules, created the oncology market’s infrastructure.

When did targeted therapy become the commercial paradigm?

NCI milestone summaries highlight trastuzumab’s emergence for HER2-positive breast cancer and imatinib’s impact in chronic myeloid leukemia as emblematic targeted-therapy breakthroughs. Those products taught investors a durable lesson: companion diagnostics and molecular selection can expand willingness-to-pay even in relatively small genetically defined populations.

The business model shift was as important as the science. Oncology R&D budgets migrated toward biomarker assays, enrichment designs, and indication sequencing — patterns still visible in today’s KRAS, HER2-low, and Claudin programs.

How did immunotherapy rewrite expectations?

Checkpoint inhibitors changed what “meaningful benefit” looked like: tails on Kaplan–Meier curves, not only median shifts. Contemporary reviews and trial registries document the rapid spread of PD-1/PD-L1 and CTLA-4 blockade across tumor types, then into combinations with chemotherapy, targeted agents, and antibody-drug conjugates.

• Chemo era: cytotoxic intensity and supportive care
• Targeted era: genotype-matched small molecules and monoclonals
• IO era: durable responses and combination stack ranking
• Current wave: ADCs, cell therapy, and multispecifics extending those logics

For a concrete modern trial artifact, registries such as ClinicalTrials.gov NCT05585684 illustrate how contemporary protocols continue to layer IO and targeted hypotheses — the operational descendants of earlier milestone classes.

What should strategists take from the timeline?

Each era created stranded assets: chemotherapies displaced by targeted standards, then some targeted niches pressured by IO combinations. A PMC oncology progress synthesis in the current literature underscores how rapidly standards evolve once a mechanism class proves ambulatory outpatient feasibility and payer pathways.

BD diligence should therefore price not only peak sales of a new modality but the displacement risk to the prior standard within five years — the recurring pattern from trastuzumab onward.

Where do ADCs and cell therapy sit on the timeline?

Antibody-drug conjugates and engineered cell therapies are not a break with history so much as a recombination of prior eras: monoclonal targeting precision plus cytotoxic payloads, or immune activation with living drugs. Deal premiums in 2024–2026 for ADC platforms echo the post-imatinib scramble for kinase franchises and the post-checkpoint scramble for IO combinations.

Strategists should therefore ask which historical analogy fits a given asset. A biomarker-restricted ADC behaves more like early trastuzumab economics. A tumor-agnostic IO combination behaves more like PD-1 label expansion plays. Mis-analogizing leads to wrong peak-sales curves.

What remains incomplete in any “brief history”?

Milestone lists compress failures, geographic inequality, and toxicity learning curves. They also under-weight diagnostics and radiation advances. Treat NCI timelines as orientation, then verify each commercial claim against labels and primary trial publications before using history as diligence evidence.

Related NovaPharma coverage

• Merck–Harpoon oncology pipeline acquisition
• Cardiff Oncology pipeline update
• EMA backs datopotamab deruxtecan

Frequently Asked Questions

Primary Sources

1. NCI: 250 Years of Advances in Cancer Research milestones
2. PMC: Contemporary oncology progress synthesis
3. ClinicalTrials.gov: Example modern oncology protocol NCT05585684